MaxCyte to Participate in Two Upcoming Investor Conferences
MaxCyte (Nasdaq: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Stifel 2024 Healthcare Conference on November 18th at 10:55 AM ET and the Stephens Annual Investment Conference on November 19th at 3:00 PM CT. Interested parties can access live and archived webcasts of both events through MaxCyte's investor relations website.
MaxCyte (Nasdaq: MXCT; LSE: MXCT), un'azienda specializzata in tecnologia di ingegneria cellulare, ha annunciato la sua partecipazione a due prossimi convegni per investitori. L'azienda prenderà parte a discussioni informali alla Stifel 2024 Healthcare Conference il 18 novembre alle 10:55 AM ET e alla Stephens Annual Investment Conference il 19 novembre alle 3:00 PM CT. Le parti interessate possono accedere alle trasmissioni in diretta e archiviate di entrambi gli eventi tramite il sito web delle relazioni con gli investitori di MaxCyte.
MaxCyte (Nasdaq: MXCT; LSE: MXCT), una empresa de tecnología de ingeniería celular, ha anunciado su participación en dos próximas conferencias para inversores. La empresa participará en charlas informales en la Stifel 2024 Healthcare Conference el 18 de noviembre a las 10:55 AM ET y en la Stephens Annual Investment Conference el 19 de noviembre a las 3:00 PM CT. Las partes interesadas pueden acceder a transmisiones en vivo y archivadas de ambos eventos a través del sitio web de relaciones con inversores de MaxCyte.
맥사이틀 (Nasdaq: MXCT; LSE: MXCT), 세포 공학 플랫폼 기술 회사는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 Stifel 2024 Healthcare Conference에서 11월 18일 오전 10시 55분 ET와 Stephens Annual Investment Conference에서 11월 19일 오후 3시 CT에 간담회에 참여할 예정입니다. 관심 있는 분들은 맥사이틀의 투자자 관계 웹사이트를 통해 두 행사 모두의 실시간 및 기록된 웹캐스트에 접근할 수 있습니다.
MaxCyte (Nasdaq: MXCT; LSE: MXCT), une entreprise de technologie de plateforme d'ingénierie cellulaire, a annoncé sa participation à deux prochaines conférences d'investisseurs. L'entreprise participera à des discussions informelles lors de la Stifel 2024 Healthcare Conference le 18 novembre à 10h55 ET et de la Stephens Annual Investment Conference le 19 novembre à 15h00 CT. Les parties intéressées peuvent accéder aux webcasts en direct et archivés des deux événements via le site Web des relations avec les investisseurs de MaxCyte.
MaxCyte (Nasdaq: MXCT; LSE: MXCT), ein Unternehmen der Zelltechnik-Plattformtechnologie, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an informellen Gesprächen auf der Stifel 2024 Healthcare Conference am 18. November um 10:55 Uhr ET und der Stephens Annual Investment Conference am 19. November um 15:00 Uhr CT teilnehmen. Interessierte Parteien können über die Investor-Relations-Website von MaxCyte auf Live- und Archivübertragungen beider Veranstaltungen zugreifen.
- None.
- None.
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences.
- Stifel 2024 Healthcare Conference
Fireside Chat on Monday, November 18th at 10:55 AM ET
- Stephens Annual Investment Conference
Fireside Chat on Tuesday, November 19th at 3:00 PM CT
A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines+1 540-629-3137
jvines@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
FAQ
When is MaxCyte (MXCT) presenting at the Stifel 2024 Healthcare Conference?
What time is MaxCyte's (MXCT) fireside chat at the Stephens Annual Investment Conference?
Where can I watch MaxCyte's (MXCT) investor conference presentations?
Which investor conferences is MaxCyte (MXCT) attending in November 2024?
